Table 1 Clinical presentation
From: Validation of IgA nephropathy diagnosis in the Swedish Renal Registry
Clinical features | n = 139 |
|---|---|
Age (years, median [range]) Male (years, mean) Female (years, mean) | 46 [18–85] 46.5 43.3 |
Sex (male:female n; %) | 94:45 (67.6:32.4) |
Heredity of kidney disease (n, %) | 8/127 (6.3) None for known IgAN |
CKD (Chronic kidney disease) stage ≥ 3 (n; %) | 80 (57.6) |
Hypertension (Blood pressure, BP > 140 and/or > 80 mmHg or Antihypertensive medications) (n; %) | 97 (69.8) |
Malignant hypertension (BP > x/120 mmHg) (n; %) | 5 (3.6) |
Proteinuria (U-albumin/creatinine ratio, U-ACR > 3 g/mole) (n; %) | 138 (99.3) |
Hematuria (Positive dipstick or sediment) (n; %) | 132 (94.7) |
Nephrotic syndrome (n; %) | 8 (5.8) |
Purpura (n; %) Cases classified as IgA Vasculitis Age, years, median [range] Creatinine (µmol/L; median [range]) eGFR (estimated Glomerular Filtration Rate, mL/min/1.73m2; median [range]) | 19 (13.6) 18 (12.9) 50 [18–85] 86 [55–173] 77 [34–125] |
Laboratory features | |
Creatinine (µmol/L; median [range]) | 123 [51-1331] |
eGFR (mL/min/1.73m2; median [range]) | 51 [5-125] |
CKD 1–2 (eGFR ≥ 60) (n; %) | 59 (42.4) |
CKD 3a (eGFR ≥ 45 and < 60) (n; %) | 20 (14.4) |
CKD 3b (eGFR ≥ 30 and < 45) (n; %) | 33 (23.7) |
CKD 4 (eGFR < 30) (n; %) | 22 (15.8) |
CKD 5 (eGFR < 15) (n; %) | 5 (3.6) |
Systolic BP (mmHg, mean ± SD) | 133.3 (± 15.6) |
Diastolic BP (mmHg, mean ± SD) | 79.8 (± 9.9) |
U-albumin/creatinine ratio (mean ± SD) n; % U-ACR < 30 g/mole, n; % U-ACR > 30 g/mole | 135.2 (± 129.4) 28 (20.1) 111 (79.9) |
Antineutrophilic cytoplasmic antibodies (n; %) | 1/114 (0.9) * |
Antinuclear antibodies/anti-dsDNA (n; %) | 8/98 (8.2) All anti-dsDNA negative |
Serum/Urine electrophoresis with monoclonality (n; %) | 1/114 (0.9) ** |
HIV (n; %) | 0/90 (0.0) |
Viral Hepatitis (n; %) [B/C] | 2/94 (2.1) [1/1] |
Complications post-biopsy | 13/139 (9.4) |
Symptomatic hematoma (pain) | 10 |
Macroscopic hematuria | 3 |
Severe complications | 0 |